GLI GLI Quality Tool
GLI Quality Tool — Version 2.0

Mapping TB lab quality indices to strategic objectives

A busy TB laboratory can have strong technical controls yet struggle to show that those controls advance the organisation’s priorities. Timely smear results, safe handling, competent staff and complete records matter, but their strategic value becomes clear when tied to explicit organizational objectives: earlier diagnosis, safer care, equitable access, reliable reporting or resilient capacity. Mapping turns separate controls into a coherent management argument.

The GLI Quality Tool offers a practical starting point. Its four-phase roadmap and twelve Quality Systems Essentials connect safety, personnel, equipment, documentation, assessment and continual improvement. Rather than treating these essentials as a compliance checklist, laboratories can use them as the evidence base for linking performance to agreed outcomes.

Each quality index, often managed as a key performance indicator, should answer a decision question. A specimen rejection rate is not just a number: if it delays diagnosis in remote communities, it may reveal weaknesses in transport, request quality or result communication. Likewise, an external quality assessment discrepancy supports confidence only when it is investigated, corrected and checked for recurrence.

The approach works for regional services and reference laboratories, provided measures remain understandable to clinicians, board members and funders. Every retained index needs an owner, a review rhythm and a plausible management action. The result is a lean quality scorecard that supports daily operations and long-term planning.

Define strategic outcomes before selecting measures

Begin with the strategic plan, not the laboratory spreadsheet. Identify two to four outcomes the organisation prioritises, such as shortening the interval from specimen receipt to a validated TB result, ensuring critical findings reach treating clinicians, maintaining safety during staffing changes or reducing avoidable repeat collection. State each outcome in plain language and define the population, timeframe and boundary of the measurement.

Separate outputs from outcomes. “Two staff attend training” is an output; “all staff working at the smear microscopy bench hold current competency authorisation” is a condition linked to quality. “Every urgent specimen is processed promptly” may still fail if results are not communicated. Strategic mapping should preserve the chain from activity, through laboratory process, to patient or service effect.

Create a short measurement charter for each objective. Record the intended result, accountable role, relevant GLI Quality Systems Essentials, data owner, review frequency and action threshold. Leadership can then see which indices are decision-relevant and which are merely available. The charter also prevents a lagging outcome from being attributed entirely to the laboratory without examining influences outside its control.

Convert quality controls into actionable indices

Quality indices work best when they cover several dimensions without creating a crowded dashboard. Safety indices can track training completion, exposures, corrective actions and audit findings. People indices can cover competency, vacancies and succession. Process indices can address turnaround, specimen rejection, invalid rates, critical notifications and stock availability. System indices can examine document control, EQA performance, corrective-action closure and staff feedback.

Give every index a precise definition: numerator, denominator, eligible cases, data source, reporting period and exclusions. Stratify results where interpretation could change. A median turnaround time may conceal a small group of urgent specimens waiting much longer, while a single combined turnover rate can hide rural, urban and Aboriginal and Torres Strait Islander differences. Small numerators should be shown as counts as well as percentages and paired with context.

Australian conditions make this especially important. In a federated system of state and territory health services, public hospital laboratories and interstate referral networks, the same indicator can operate differently in Perth, Melbourne, Darwin and Cairns. Specimens may travel long distances, severe weather can disrupt flights or roads, and a same-day result at a metropolitan laboratory may be impossible for a remote clinic. Record these constraints beside the target rather than treating them as excuses.

Build a traceable indicator-to-objective chain

The core mapping chain is: strategic objective, quality essential, process, risk, index, target, evidence source, owner, review trigger and improvement action. Work through it in that order. This prevents activity-based measures, such as the number of SOPs written, from being mistaken for strategic results. It also exposes gaps: if an objective depends on timely transport but no index covers transport time, the scorecard cannot support the claim.

Use a cross-functional group rather than a purely technical review. Include a laboratory manager, quality lead, scientist, microbiology representative, clinician or program partner, biosafety contact and, where possible, someone familiar with the patient journey. In Australian laboratory parlance, “sign-off” means documented authorisation, so define who signs off on targets, outlier responses and changes to the measurement charter.

Mapping actions for leadership and laboratory teams

For the leadership workshop

For the laboratory team

Review the chain at a fixed monthly or quarterly forum. Confirm whether each index still measures what management believes it measures, whether missing data affect interpretation and whether corrective actions are effective. Retire duplicated measures, but retain a short record of why each was removed. A smaller map that people trust is more useful than an exhaustive catalogue that sits in a policy file.

Use GLI phases to stage implementation

Stage the work with the GLI Quality Tool rather than attempting to create a comprehensive system at once. Use the early phase to establish governance, document ownership, essential policies and baseline data. During implementation, test indicator definitions in live reporting. The review phase can compare trends and assess whether controls operate consistently, while the improvement phase turns persistent gaps into funded change.

The tool’s phase-specific checklists, user instructions and downloadable materials can become meeting agendas and evidence repositories. For technical procedures, the GLI advice on smear microscopy SOP guidance gives laboratories a practical way to connect standardised task steps with competence, safety, quality control and document control. Each mapped index can then point to a specific procedure or record, reducing ambiguity during review.

Many Australian laboratories also work within NATA accreditation requirements and ISO 15189 expectations. Treat these requirements as an assurance backbone, not as the strategy itself. An accredited process may still need an additional index for transport delays or patient communication. Conversely, avoid creating a parallel quality framework when an existing committee, risk register, audit schedule or business-intelligence report can carry the measure.

Compare indicators across strategic value

A balanced indicator set should include a small number of outcome measures, several process indicators and a few sentinel safety or quality checks. Define thresholds before reviewing performance, using baselines and clinical risk rather than copying percentages from another jurisdiction. Where data are immature, use counts and descriptive trends until a stable denominator is available.

Strategic objective TB laboratory quality index Core evidence Management response
Earlier reliable diagnosis Median receipt-to-result time for urgent specimens LIMS timestamps and request category Investigate delays and escalate persistent outliers
Safer care Critical result notification within policy Notification and escalation records Review failed contacts and strengthen escalation
Equitable access Repeat collection rate by service area and relevant patient groups Rejection and recollection logs Examine transport, request quality and point-of-care pathways
Assured results EQA discrepancy rate and corrective-action closure EQA reports and improvement records Trigger root-cause review and verify recurrence
Workforce resilience Competency currency and planned roster gaps Training records, rosters and vacancy data Schedule sign-off before independent work resumes

The comparison shows why a direct strategic link matters. Turnaround time may support faster diagnosis, but it will not reveal every cause of delay; EQA performance supports confidence in results, but it does not show whether critical findings were acted upon. Interpret each index with its paired operational measure, and ensure no important objective depends solely on one source of data.

Launch a focused improvement cycle

Start with one improvement pathway rather than launching the entire scorecard. Select an objective with visible clinical value, confirm the baseline, assign one owner and agree on a 90-day test. For example, focus on urgent TB result notification in a specific service, review every delayed communication and determine whether the cause lies in testing, result release, LIS routing or clinician contact.

During the review, determine what changed, for whom and whether the change is worth sustaining. Adjust a target only with a documented rationale. Capture before-and-after measures, staff feedback and resource implications so the executive sponsor can make an evidence-based decision. Share lessons from local adaptation through the GLI Quality Tool’s implementation feedback channel, recording the context and management response as well as the result.

Begin by opening the relevant GLI phase, bringing together the people who own the process and those who use the result, and mapping a single objective to a defensible quality index. In the next quarterly review, present the baseline, management action and evidence of benefit. Expand the map only where an additional index has a clear decision attached to it.